BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

Grant

Total Award Amount

  • 28636.00
  • Direct Costs

  • 19284.00
  • Sponsor Award Id

  • 10022
  • Contributor

  • Racquel Innis-Shelton M.D.   Principal Investigator